title: [Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].
abstract: BACKGROUND
  Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel.
  
  
  METHODS
  S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery.
  
  
  RESULTS
  Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10% patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20% patients (n=2).
  
  
  CONCLUSIONS
  We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.
authors.affiliation: Dept. of Surgery, Saiseikai Yokohamashi Tobu Hospital, Japan.
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Egawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kemmochi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Irino
authors.forename: Koki
authors.initials: K
authors.lastname: Mihara
authors.forename: Akihiko
authors.initials: A
authors.lastname: Okamura
authors.forename: Eiichi
authors.initials: E
authors.lastname: Etoh
authors.forename: Yusaku
authors.initials: Y
authors.lastname: Inaba
authors.forename: Kenki
authors.initials: K
authors.lastname: Segami
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Ito
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagashima
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid